Bristol-Myers Squibb (BMS) has announced plans for a new cell-therapy manufacturing site in Leiden, the Netherlands.

Planning for site design and development is underway with construction slated to begin later this year (2021). Leiden will be BMS’ fifth cell-therapy manufacturing facility and its first in Europe. The European facility will be commercially focused with capabilities for multi-product cell-therapy manufacturing with the ability to scale up capacity.

Earlier this year (February 2021), BMS started construction for a new cell-therapy manufacturing facility at its biomanufacturing site in Devens, Massachusetts.

Source: Bristol-Myers Squibb